{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:00:43Z","timestamp":1780639243356,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Soft tissue sarcoma is highly heterogeneous, and clear cell sarcoma (CCS) is a rare, aggressive subtype prone to recurrence and lymph node or lung metastasis. This report describes a patient with upper-limb CCS who developed postoperative recurrence and pulmonary metastasis. After transient benefit from first-line doxorubicin plus ifosfamide chemotherapy, the disease progressed despite second-line PD-1 inhibitor combined with anlotinib. Treatment was subsequently switched to cadonilimab, a PD-1\/CTLA-4 bispecific antibody, in combination therapy, resulting in a progression-free survival of more than 24 months. This outcome appears encouraging compared with previously reported CCS benchmarks; however, given the single-case nature and combined treatment strategy, the specific contribution of cadonilimab should be interpreted with caution.<\/jats:p>","DOI":"10.3389\/fonc.2026.1699788","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:08:31Z","timestamp":1780636111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cadonilimab in the treatment of advanced metastatic soft tissue clear cell sarcoma achieved complete remission: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanzhe","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3045","article-title":"Clinicopathologic re-evaluation of 100 Malignant fibrous histiocytomas: prognostic relevance of subclassification","volume":"19","author":"Fletcher","year":"2001","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/his.14265","article-title":"Updates from the 2020 world health organization classification of soft tissue and bone tumours","volume":"78","author":"Anderson","year":"2021","journal-title":"Histopathology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2693-6","article-title":"The epidemiology and survivorship of clear cell sarcoma: a National Cancer Database (NCDB) review","volume":"144","author":"Gonzaga","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001658","article-title":"Clear cell sarcoma with cutaneous presentation in a 4-year-old boy","volume":"42","author":"Westover","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16038","article-title":"Establishment and characterisation of human clear cell sarcoma and Malignant melanoma cell lines","volume":"42","author":"Ishiguro","year":"2022","journal-title":"Anticancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146301","article-title":"The clear cell sarcoma functional genomic landscape","volume":"131","author":"Panza","year":"2021","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900115)65:2<367::AID-CNCR2820650232>3.0.CO;2-X","article-title":"Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors","volume":"65","author":"Sara","year":"1990","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.01.016","article-title":"Clear cell sarcoma of soft tissue: a retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli","volume":"40","author":"Bianchi","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/jjco\/hyad083","article-title":"The current management of clear cell sarcoma","volume":"53","author":"Ikuta","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2183846","article-title":"Clear cell sarcoma: state-of-the art and perspectives","volume":"23","author":"Wetterwald","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02222-0","article-title":"Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma","volume":"128","author":"Rasmussen","year":"2023","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35483","article-title":"Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial\/NCCH1510)","volume":"130","author":"Nishikawa","year":"2024","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1694490","article-title":"Recent progress in cadonilimab research for oncology applications","volume":"16","author":"Dong","year":"2026","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03007-5","article-title":"Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial","volume":"30","author":"Gao","year":"2024","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9502-7","article-title":"Chemotherapy in clear cell sarcoma","volume":"28","author":"Jones","year":"2011","journal-title":"Med Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100522","article-title":"Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network","volume":"7","author":"Smrke","year":"2022","journal-title":"ESMO Open"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx527","article-title":"Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 \u2018CREATE\u2019","volume":"28","author":"Sch\u00f6ffski","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1699788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:08:32Z","timestamp":1780636112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1699788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1699788"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1699788","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1699788"}}